LPTX - Leap Therapeutics, Inc.
| Previous Close | 1.4800 |
| Open | 1.5100 |
| Bid | 1.4900 x 800 |
| Ask | 1.5000 x 900 |
| Day's Range | 1.4400 - 1.5302 |
| 52 Week Range | 1.3500 - 8.1730 |
| Volume | 143,250 |
| Avg. Volume | 353,167 |
| Market Cap | 35.96M |
| Beta (3Y Monthly) | 3.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.6630 |
| Earnings Date | Nov 15, 2018 - Nov 16, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.83 |
- PR Newswire
Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination at the 2019 International Gynecologic Cancer Society Annual Global Meeting
- DKN-01 Monotherapy Patient with an Ongoing Complete Response - Enhanced PFS in patients with Wnt Activating Mutations and DKK1 -high Tumors CAMBRIDGE, Mass. , Sept. 17, 2019 /PRNewswire/ -- Leap Therapeutics, ...
- PR Newswire
Leap Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. , Sept. 4, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. ...
- PR Newswire
Leap Therapeutics Reports Second Quarter 2019 Financial Results
- Positive data from DKN-01 plus KEYTRUDA® (pembrolizumab) combination study - First patients enrolled in TRX518 plus BAVENCIO® (avelumab) and cyclophoshamide combination study CAMBRIDGE, Mass. , Aug. ...
- PR Newswire
Leap Presents Positive Clinical Results for the Combination of DKN-01 plus Keytruda® and Provides DKN-01 Program Update
-- Enhanced survival outcomes in DKK1 -high gastroesophageal junction and gastric cancer patients - -- DKK1 -high biomarker enables future patient selection - -- Live conference call and webcast with clinical ...
- PR Newswire
Leap Therapeutics to Host Conference Call to Provide DKN-01 Program Update
Conference call and webcast to be held August 6, 2019 at 8:30 a.m. ET CAMBRIDGE, Mass. , July 25, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing ...
- PR Newswire
Leap Therapeutics Announces Common Stock Purchase Agreements For Up to $21 Million with Lincoln Park Capital
CAMBRIDGE, Mass., July 11, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced it has entered into common stock purchase agreements for up to $21 million with Lincoln Park Capital Fund, LLC ("LPC"), a Chicago-based institutional investor and current shareholder. Under a purchase agreement dated July 11, 2019, LPC agreed to purchase $1,000,000 of Leap's registered common stock at a price of $1.75 per share (the "July 11 Purchase Agreement").
- PR Newswire
Leap Therapeutics to Present at the 2019 Raymond James Life Sciences and MedTech Conference
CAMBRIDGE, Mass. , June 11, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. ...
- Simply Wall St.
Investors Who Bought Leap Therapeutics (NASDAQ:LPTX) Shares A Year Ago Are Now Down 82%
The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...
- PR Newswire
Leap Therapeutics Reports First Quarter 2019 Financial Results
- Strong clinical trial enrollment leading to significant 2019 data - First patient enrolled in DKN-01 prostate cancer study CAMBRIDGE, Mass. , May 15, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: ...
- PR Newswire
Leap Therapeutics to Present at the 2019 Needham & Company 18th Annual Healthcare Conference
CAMBRIDGE, Mass. , April 3, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Christopher ...
- PR Newswire
Leap Therapeutics Reports Clinical Update and 2018 Financial Results
CAMBRIDGE, Mass. , April 1, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported an update on its clinical ...
- PR Newswire
Leap Therapeutics Presents at Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer
CAMBRIDGE, Mass., March 18, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (LPTX) today announced the presentation of clinical data from its ongoing Phase 2 clinical trial of DKN-01 in patients with advanced gynecological malignancies at the Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer. Patients, including those with carcinosarcoma and Wnt pathway alterations, have experienced partial responses and durable clinical benefit in both the monotherapy and combination arms of the study. The complete data set will become available in the coming months as the most recently enrolled patients have yet to be evaluated.
- ACCESSWIRE
Four Tech Stocks Setting The Pace On Monday
CORAL GABLES, FL / ACCESSWIRE / March 11, 2019 / The success of the tech stock market is directly correlated to the operating assumption that tech companies are prepared to meet the rising challenges presently facing society. As we've seen in the first few months of 2019, the tech sector is booming with the excitement surrounding companies working on advanced technologies meant to take humanity into the future. ParcelPal Technology Inc (PTNYF) (PKG), Plug Power Inc (PLUG), Leap Therapeutics Inc (LPTX) and NantHealth Inc (NH) represent 4 tech stocks on the rise on Monday.
- PR Newswire
Leap Therapeutics to Present at the Society of Gynecologic Oncology 2019 Annual Meeting on Women's Cancer
CAMBRIDGE, Mass. , March 8, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company ...
- GuruFocus.com
Leap Therapeutics Inc (LPTX) CEO, President, Chairman Christopher Mirabelli Bought $999,999 of ...
CEO, President, Chairman of Leap Therapeutics Inc (NASDAQ:LPTX) Christopher Mirabelli bought 571,428 shares of LPTX on 02/05/2019 at an average price of $1.75 a share.
- PR Newswire
Leap Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Securities
CAMBRIDGE, Mass., Feb. 5, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of an underwritten public offering of 6,571,428 shares of its common stock and warrants to purchase up to 6,571,428 shares of its common stock, as well as an additional 985,714 shares of its common stock and warrants to purchase up to 985,714 shares of its common stock pursuant to the full exercise of the underwriters' option to purchase additional securities. Total gross proceeds to Leap from this offering were approximately $13,225,000, before deducting underwriting discounts and offering expenses payable by Leap, and excluding any proceeds Leap may receive upon exercise of the warrants. Raymond James & Associates, Inc. and Ladenburg Thalmann acted as book-running managers for the offering.
- PR Newswire
Leap Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock and Warrants
CAMBRIDGE, Mass., Feb. 1, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of 6,571,428 shares of its common stock and warrants to purchase up to 6,571,428 shares of its common stock. Each share of common stock is being sold together with a warrant to purchase one share of common stock for a combined offering price of $1.75 per share and accompanying warrant. The gross proceeds to Leap from this offering are expected to be approximately $11.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Leap and excluding the proceeds from the exercise of any warrants.
- PR Newswire
Leap Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
CAMBRIDGE, Mass., Jan. 31, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has commenced an underwritten public offering of its common stock and warrants to purchase common stock. All shares of common stock and warrants to be sold in the offering will be offered by Leap. Leap intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15% of the shares of its common stock and/or warrants to purchase shares of its common stock offered in the public offering.
- TheStreet.com
2 Small-Cap Biotech Stocks That Are on My Radar
After a dismal fourth quarter, the biotech sector got off to a hot start in 2019 on the back of a couple of major buyouts in the space to start the New Year. The rally then ebbed as no more M&A deals emerged -- see the chart of the SPDR S&P Biotech ETF , below.
- GlobeNewswire
Report: Developing Opportunities within Match Group, Antero Resources, Boyd Gaming, Gorman-Rupp, Leap Therapeutics, and BioPharmX — Future Expectations, Projections Moving into 2019
NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire
Leap Therapeutics Announces an Investigator-Initiated Study of DKN-01 in Patients with DKK1+ Advanced Prostate Cancer
CAMBRIDGE, Mass. , Jan. 14, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced an investigator-initiated ...
- PR Newswire
Leap Therapeutics Presents TRX518 Data at ESMO Immuno-Oncology Congress 2018 and Updated Data from DKN-01 Study in Biliary Tract Cancer
TRX518 (GITR Agonist) Clinical Perspectives conference call and webcast on Monday, December 17 at 8:30 AM ET CAMBRIDGE, Mass. , Dec. 14, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today ...
- PR Newswire
Leap Therapeutics Reports Third Quarter 2018 Business Update and Financial Results
CAMBRIDGE, Mass. , Nov. 9, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported a business update and ...
- PR Newswire
Leap Therapeutics Presents Esophagogastric Cancer Data at SITC 2018 Annual Meeting
CAMBRIDGE, Mass. , Nov. 9, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today presented clinical data from its ongoing Phase I/II study of DKN-01 in combination with paclitaxel in patients ...
- PR Newswire
Leap Therapeutics Presents Esophagogastric Cancer Data at ESMO 2018 Annual Congress
-- Live conference call and webcast on Monday, October 22 at 8:00 AM ET -- CAMBRIDGE, Mass. , Oct. 21, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX) today presented clinical data from its ...
